Gastric , GEJ and Esophageal cancer studies recruiting patients need your help. Receive premium care & cutting edge treatments by enrolling in clinical trials today.

Top 10 Gastric Cancer Trials [2024 Studies] | Power

Gastric Cancer Clinical Trials

Gastric cancer studies recruiting patients for novel treatments. Filter by phase, distance, and inclusion criteria to find your perfect clinical trial.

No Placebo-Only Group

The purpose of this study is to find out whether combining nivolumab, FOLFOX, and regorafenib may be a safe and effective treatment for people who have HER2-negative metastatic esophagogastric cancer.

Nivolumab is an antibody, like the proteins made by the immune system to protect the body from harm. Nivolumab blocks the protein PD-1 (programmed cell death receptor-1) that usually acts as a "brake" on the immune system. Blocking this protein is like releasing the brakes, so that the immune system can target cancer cells and destroy them.

FOLFOX is a combination of three standard chemotherapy drugs (leucovorin, 5-fluorouracil, and oxaliplatin) commonly used to treat your type of cancer. The drugs work by damaging the DNA in cancer cells, which can cause the cells to stop growing and die.

Regorafenib is a type of drug called a tyrosine kinase inhibitor (TKI). This drug targets the tyrosine kinase protein found in or on the surface of cancer cells that the cells need to survive and grow. Blocking this protein may stop cancer cells from growing, or cause them to grow more slowly or to shrink.

The study researchers think that combining nivolumab, FOLFOX, and regorafenib may be a more effective treatment for HER2-negative metastatic esophagogastric cancer than the usual chemotherapy treatment(s) alone.

A Study of Nivolumab Combined With FOLFOX and Regorafenib in People Who Have HER2-Negative Esophagogastric Cancer

Nivolumab + FOLFOX + Regorafenib for Esophageal Cancer

You have already received treatment with regorafenib.

You have vitiligo or alopecia (hair loss).

You have cancer that has spread to your brain or the lining around your brain.

You have already received treatment with a specific kind of medication that targets proteins called PD-1, PD-L1, or PD-L2.

You have a lung condition called pneumonitis that is not caused by an infection and is currently active.

You have underactive thyroid or a condition called Hashimoto syndrome, but it is being treated with hormone replacement therapy.

Nivolumab

FOLFOX chemotherapy with oxaliplatin

Regorafenib

This is a single-center, open-label, non-randomized, uncontrolled Phase 1 study of intraperitoneal docetaxel in combination with systemic mFOLFOX6 for patients who have gastric cancer with gross peritoneal carcinomatosis (GC-PC).

Intraperitoneal Docetaxel in Combination With mFOLFOX6 for Gastric Cancer Patients With Peritoneal Carcinomatosis

Intraperitoneal Chemotherapy for Stomach Cancer

This study is evaluating whether a combination of chemotherapy and a drug called docetaxel may help treat gastric cancer.

I agree to use contraception during and for 4 months after the study.

I am willing to have a port placed inside my abdomen.

I haven't had a monoclonal antibody treatment in the last 4 weeks or have recovered from its side effects.

I have moderate to severe numbness, tingling, or pain in my hands or feet.

I am not taking drugs that affect the enzyme CYP3A4.

I have received radiotherapy in my pelvic or abdominal area.

I am using two birth control methods or am not having sex to join this study.

My organ functions are normal as per recent tests.

My gastric cancer affects the area near my esophagus or the beginning of my small intestine.

I am currently taking antibiotics for an infection.

My cancer has not spread to distant parts of my body as confirmed by scans.

I have another cancer besides the one being studied, but it's not getting worse or needing treatment, except for certain skin cancers or treated cervical cancer.

I am fully active or restricted in physically strenuous activity but can do light work.

I haven't had cancer treatment in the last 4 weeks, or I've recovered from its side effects.

My gastric cancer was confirmed without prior chemo for advanced stages.

I have an immune system disorder or have been on steroids or other immune-weakening medicines in the last week.

My cancer has spread to my brain or its coverings.

I am not allergic to docetaxel or mFOLFOX6.

I have had surgery before that resulted in thick scar tissue inside my abdomen.

Docetaxel

This clinical trial is evaluating a drug called BT5528 alone and in combination with nivolumab in participants with advanced solid tumors historically known for expression of EphA2. The main goals of this study are to:

Find the recommended dose(s) of BT5528 that can be given safely to participants alone and in combination with nivolumab
Learn more about the side effects of BT5528
Learn about how effective BT5528 is for the treatment of ovarian cancer, urothelial/bladder cancer, lung cancer (NSCLC), triple-negative breast cancer, head and neck cancer (HNSCC), and gastric/upper gastrointestinal cancer.
Learn more about BT5528 therapy alone and in combination with nivolumab.

Study BT5528-100 in Patients With Advanced Solid Tumors Associated With EphA2 Expression

BT5528 for Solid Cancers

I am not on medication that strongly affects certain liver enzymes or a specific drug transporter.

I have brain metastases or leptomeningeal disease that hasn't been treated.

I have not received a live vaccine in the last 30 days.

I have a history of lung scarring or fibrosis.

I am fully active or can carry out light work.

I take more than 10 mg of prednisone or a similar strong immunosuppressant daily.

You have taken any other experimental treatments within 4 weeks before starting BT5528.

I am currently being treated for an infection.

I haven't had chemotherapy or other cancer treatments in the last 14 days.

My kidney, liver, blood, and clotting functions are normal.

My doctor believes I have at least 12 weeks to live after starting BT5528 treatment.

Any side effects from my previous treatments have mostly gone away.

I have tried all recommended treatments for my condition.

I had major surgery more than 4 weeks ago and have recovered enough to start treatment.

My cancer has spread, and I've tried all treatments without success.

I have urothelial cancer and was treated with enfortumab vedotin, but it progressed within 6 months.

I am using or willing to use effective birth control methods.

I am allergic to the trial medication or its components.

My cancer is known to often show high levels of EphA2.

I have hepatitis B but my viral load is undetectable with treatment.

You have a condition that weakens your immune system.

You have had a bad reaction to a type of medication that helps the immune system fight cancer.

You are allergic to checkpoint inhibitor therapy.

I have active hepatitis C or have been successfully treated for it.

I haven't had blood clots or bleeding issues in the last 3 months.

My blood pressure is very high and not controlled by treatment.

I have had pneumonitis and still experience symptoms.

You have a measurable disease according to specific guidelines.

You have a history of autoimmune diseases, except for alopecia or vitiligo.

I have signed and dated the consent form to participate in this study.

I haven't had cancer, except for certain skin, cervical, or breast conditions, in the last 3 years.

I haven't had a fever or taken antibiotics in the last 14 days.

I can provide a sample of my tumor for testing, or I am willing to have a biopsy.